Does Rallies show Form 4 insider transactions for STRO?

Yes. Rallies tracks STRO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is STRO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for STRO. It does not provide personalized investment advice.

STRO (Sutro Biopharma, Inc.) Stock Analysis - Insider Trades

Sutro Biopharma, Inc. (STRO) is a publicly traded Healthcare sector company. As of May 21, 2026, STRO trades at $30.52 with a market cap of $571.35M and a P/E ratio of -1.26. STRO moved -1.80% today. Year to date, STRO is +186.38%; over the trailing twelve months it is +246.00%. Its 52-week range spans $5.23 to $46.00. Analyst consensus is strong buy with an average price target of $47.50. Rallies surfaces STRO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading STRO stock inside the company?

Recent STRO insider activity includes Gerber Hans-Peter bought 17.00K, Chow Gregory K. bought 19.75K, Chung Jane bought 12.50K, MATSUI CONNIE bought 50.00K, and Pauling David bought 12.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

STRO Key Metrics

Key financial metrics for STRO
Metric	Value
Price	$30.52
Market Cap	$571.35M
P/E Ratio	-1.26
EPS	$-24.53
Dividend Yield	0.00%
52-Week High	$46.00
52-Week Low	$5.23
Volume	120
Avg Volume	0
Revenue (TTM)	$99.61M
Net Income	$-153.60M
Gross Margin	0.00%

Recent STRO Insider Trades

Gerber Hans-Peter bought 17.00K (~$13.61K) on Oct 15, 2025.
Chow Gregory K. bought 19.75K (~$16.00K) on Oct 15, 2025.
Chung Jane bought 12.50K (~$10.01K) on Oct 15, 2025.
MATSUI CONNIE bought 50.00K (~$39.95K) on Oct 15, 2025.
Pauling David bought 12.50K (~$9.99K) on Oct 15, 2025.

Latest STRO News

Sutro Biopharma Plans IND Submissions for Two ADCs, Holds $202.6M Cash — May 14, 2026
Sutro Biopharma Doses Third STRO-004 Cohort, Raises $110M to Extend Cash to 2Q 2028 — Mar 23, 2026
Sutro Biopharma Prices $110M Stock Offering at $13.98 Per Share — Feb 10, 2026

STRO Analyst Consensus

9 analysts cover STRO: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $47.50.

Common questions about STRO

Who is trading STRO stock inside the company?: Recent STRO insider activity includes Gerber Hans-Peter bought 17.00K, Chow Gregory K. bought 19.75K, Chung Jane bought 12.50K, MATSUI CONNIE bought 50.00K, and Pauling David bought 12.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for STRO?: Yes. Rallies tracks STRO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is STRO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for STRO. It does not provide personalized investment advice.